Alphamab Oncology Ordinary Shares 09966
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- HKD 4.45
- Day Range
- HKD 4.45–4.68
- 52-Week Range
- HKD 3.81–15.98
- Bid/Ask
- HKD 4.63 / HKD 4.67
- Market Cap
- HKD 4.51 Bil
- Volume/Avg
- 2.2 Mil / 2.7 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 18.52
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in discovery, development manufacturing and commercialization of biotherapeutics for cancer treatment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 435
- Website
- https://www.alphamabonc.com
Comparables
Valuation
|
Metric
|
09966
|
02171
|
06628
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.44 | 1.66 | 0.77 |
Price/Sales | 18.52 | — | 12.16 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
09966
|
02171
|
06628
|
|---|---|---|---|
Quick Ratio | 6.35 | 9.49 | 1.50 |
Current Ratio | 6.59 | 9.55 | 1.61 |
Interest Coverage | −25.61 | −174.85 | −33.53 |
Quick Ratio
09966
02171
06628
Profitability
|
Metric
|
09966
|
02171
|
06628
|
|---|---|---|---|
Return on Assets (Normalized) | −11.93% | −28.70% | −22.79% |
Return on Equity (Normalized) | −16.61% | −35.29% | −38.31% |
Return on Invested Capital (Normalized) | −15.27% | −35.38% | −26.22% |
Return on Assets
09966
02171
06628
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hxdtncwkhk | Mnfk | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vlygpcrx | Rqtngs | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ygksgjbgm | Lxhsjvt | $97.8 Bil | |
MRNA
| Moderna Inc | Bbvhttst | Skw | $41.3 Bil | |
ARGX
| argenx SE ADR | Gjksdvcb | Vwf | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Jpghxydx | Jztt | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Cyhrsctb | Ywspkf | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rxddmsjxc | Jdjptl | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Lfwxjtbwc | Hwbqyr | $12.5 Bil | |
INCY
| Incyte Corp | Wbbpxty | Zmnlcx | $11.6 Bil |